| 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 深圳华大基因（300676）科技有限公司 | 14128.56 | 34.16 | -748.83 | | 深圳生华投资企业(有限合伙) | 3447.05 | 8.34 | 不变 | | 中国银行股份有限公司-华宝中证医疗交易型开放式指数 | | | | | 证券投资基金 | 814.89 | 1.97 | -21.65 | | 中国工商银行股份有限公司-易方达创业板交易型开放式 | 596.35 | 1.44 | -47.26 | | 指数证券投资基金 | | | | | 香港中央结算有限公司 | 521.97 | 1.26 | 213.00 | | 交通银行股份有限公司-万家行业优选混合型证券投资基 金(LOF) | 500.01 | 1.21 | -100.00 | | 深圳华大三生园科技有限公司 | 393.58 | 0.95 | 不变 | | 法国巴黎银行-自有资金 | 353.04 | 0.85 | 新进 | | 深圳华大基因股份有限公 ...

Financial Performance - In 2024, the company achieved operating revenue of CNY 3,866.92 million, a year-on-year decrease of 11.10%[5]. - The net profit attributable to shareholders was a loss of CNY 902.69 million, a year-on-year decline of 1,071.68%[5]. - The decline in revenue was primarily due to industry cycles and intensified market competition, leading to a significant drop in gross margins for some products[5]. - Increased R&D investment has impacted net profit due to high costs without a corresponding significant increase in revenue[5]. - The net cash flow from operating activities decreased by 76.58% to CNY 95,722,825.51 in 2024, down from CNY 408,767,851.37 in 2023[28]. - The total assets at the end of 2024 were CNY 12,542,286,394.63, a decrease of 7.87% from CNY 13,613,007,886.01 at the end of 2023[28]. - The net assets attributable to shareholders decreased by 7.35% to CNY 9,134,857,139.18 at the end of 2024, compared to CNY 9,859,237,734.19 at the end of 2023[28]. - The basic earnings per share for 2024 was CNY -2.1890, a decline of 1,066.02% from CNY 0.2266 in 2023[28]. - The diluted earnings per share for 2024 was CNY -2.1890, down 1,071.59% from CNY 0.2253 in 2023[28]. - The weighted average return on equity for 2024 was -9.50%, a decrease of 10.43% from 0.93% in 2023[28]. - The company reported a negative net profit for the most recent three accounting years, indicating uncertainty in its ability to continue as a going concern[29]. Strategic Focus and Innovation - The company plans to focus on product and technology innovation, accelerating key product iterations and new product development[7]. - The company is leveraging AI and big data to reduce testing costs and optimize channel layouts to maintain competitive advantages[7]. - Future strategic plans and risk management measures are outlined in the management discussion section of the report[7]. - The company is committed to continuous innovation in gene technology, which is recognized as a key area for future economic growth[39]. - The company is focused on leveraging AI and big data in gene technology to enhance precision medicine and health management services[39]. Market Expansion and Partnerships - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[20]. - A new partnership with Guangzhou Zhongjian Yunkang is anticipated to increase service offerings and improve customer reach[19]. - The company has established partnerships with multiple countries along the "Belt and Road" initiative, including Saudi Arabia and Uzbekistan, to enhance local healthcare services[139]. Research and Development - The company increased its R&D investment to 676.95 million yuan, representing a year-on-year growth of 10.20%[140]. - The company is focusing on the localization of raw materials for the NIFTY non-invasive prenatal testing kit to reduce costs and enhance market competitiveness[189]. - The company has launched a new spatiotemporal omics product, enhancing its capabilities in life sciences technology applications[194]. - The company has increased its R&D personnel to 711, representing a 1.14% increase from the previous year, with a higher proportion of master's and doctoral degree holders[195]. Product Development and Offerings - The company has developed a comprehensive database, "Wanshang Database," to support its genetic testing business, covering key areas such as reproductive health, tumor diagnosis, and infection prevention[99]. - The company has launched a cervical cancer DNA methylation detection product, significantly improving the specificity of high-risk HPV screening management[149]. - The company has developed a non-invasive prenatal screening (NIPT) product that can detect both maternal genetic disease-causing genes and fetal chromosomal abnormalities from a single blood sample, significantly enhancing detection performance[143]. - The company is focusing on developing a comprehensive solution for assisted reproduction, enhancing performance and reducing costs through innovative technology[143]. Regulatory Compliance and Certifications - The company has received ISO/IEC 27001:2022 certification, becoming the first in the high-throughput gene sequencing industry to achieve this international standard[132]. - The company has obtained medical device registration certificates for three products, including a gene sequencer and two software applications for genetic testing[200]. - The company has received regulatory approvals for its colorectal cancer detection product in multiple countries, establishing a solid foundation for its global market presence[107]. Market Trends and Projections - The global gene testing market is projected to grow from 19.66 billion USD in 2024 to 32.83 billion USD by 2029, with a CAGR of 10.81%[40]. - China's gene testing market is entering a high growth phase, driven by a large population base and increasing health awareness[40]. - The cancer screening market was valued at approximately $172.3 billion in 2022 and is expected to grow to $293.6 billion by 2030, indicating significant growth potential in the industry[48]. - The global digital health market is projected to reach approximately $296.46 billion in 2024, with a compound annual growth rate (CAGR) of 17.2% expected until 2029, highlighting the vast potential of multi-omics big data services in the health sector[59]. Operational Efficiency and Cost Management - The company has implemented a supply chain management system to enhance procurement efficiency and ensure product quality through a rigorous supplier evaluation process[79]. - The production model includes clinical development and application services, ensuring product quality through strict quality control processes at key production stages[81]. - The company has implemented security measures for the OmicsDB platform, including classification, auditing, encryption, and desensitization of stored data, ensuring data safety and compliance[101]. Customer Engagement and Service Delivery - The company has established medical device operation centers in over ten provinces in China and international locations, enhancing its global service capabilities[84]. - The company has launched a series of rapid testing products for home use, including COVID-19 antigen test kits and influenza virus antigen test kits, to meet the demand for quick pathogen identification[110]. - The company has trained approximately 113 hospitals on high-throughput sequencing data analysis and interpretation, covering fertility, oncology, and infection products[118].

Financial Performance - The company's revenue for Q1 2025 was ¥671,910,156.79, representing a decrease of 18.18% compared to ¥821,250,378.55 in the same period last year[2]. - The net profit attributable to shareholders was a loss of ¥52,695,120.08, a decline of 524.87% from a profit of ¥12,402,522.05 in the previous year[2]. - The net cash flow from operating activities was -¥397,093,777.71, a decrease of 422.92% compared to -¥75,937,361.58 in the same period last year[2]. - The basic earnings per share were -¥0.1278, down 521.78% from ¥0.0303 in the same period last year[2]. - The decline in performance was primarily due to a decrease in revenue scale and slower-than-expected collection of accounts receivable, leading to increased credit impairment losses compared to the previous year[10]. - Total operating revenue for the current period is ¥671,910,156.79, a decrease of 18.2% from ¥821,250,378.55 in the previous period[24]. - Net profit for the current period is a loss of ¥55,295,405.94, compared to a profit of ¥12,150,258.43 in the previous period[25]. - The basic earnings per share for the current period is -0.1278, compared to 0.0303 in the previous period, indicating a significant decline[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥12,595,327,557.05, an increase of 0.42% from ¥12,542,286,394.63 at the end of the previous year[2]. - Total liabilities increased to ¥3,360,188,917.99 from ¥3,270,676,576.56, marking a rise of 2.7%[23]. - The company’s total equity stands at ¥9,235,138,639.06, slightly up from ¥9,271,609,818.07 in the previous period[23]. - The company's total current assets amounted to RMB 6,888,220,016.77, slightly up from RMB 6,875,791,256.55 at the beginning of the period[21]. - The company's fixed assets increased to RMB 2,601,833,058.56 from RMB 2,578,695,623.85[21]. Cash Flow - The company's cash flow statement indicates a need for improved cash management strategies, as indicated by the current financial performance[27]. - Operating cash inflow for the current period was $652.49 million, down from $777.11 million in the previous period, representing a decrease of approximately 16.06%[28]. - Net cash flow from operating activities was -$397.09 million, compared to -$75.94 million in the previous period, indicating a significant decline[28]. - Cash inflow from investment activities totaled $1.84 billion, an increase from $1.08 billion in the prior period, reflecting a growth of about 70.38%[28]. - Cash inflow from financing activities was $570.96 million, a substantial increase from $32.40 million in the previous period, marking a growth of approximately 1,661.73%[29]. - The ending cash and cash equivalents balance was $2.63 billion, down from $2.91 billion in the previous period[29]. - The company experienced a negative net increase in cash and cash equivalents of -$68.26 million, compared to -$644.24 million in the previous period, indicating an improvement[29]. Shareholding Structure - As of the report date, the controlling shareholder, Huada Holdings, and its concerted parties held 147,759,217 shares, accounting for 35.53% of the total share capital[13]. - A total of 10,484 million shares held by the controlling shareholder were pledged, representing 70.95% of their holdings and 25.21% of the total share capital[13]. - Huada Holdings transferred 10.5% of its equity to a company wholly owned by the actual controller, Wang Jian, resulting in an increase in Wang Jian's direct and indirect shareholding from 31.90% to 35.75%[14]. - The overall shareholding and voting rights of Huada Holdings and its concerted parties remained unchanged at 37.34%[14]. - The company’s major shareholders include Shenzhen Huada Gene Technology Co., Ltd. with 141,285,593 shares and Shenzhen Huada San Shengyuan Technology Co., Ltd. with 34,470,455 shares[12]. - The company has not disclosed any significant changes in the shareholding structure of the top 10 shareholders due to margin trading activities[10]. - The controlling shareholder, BGI Holdings, plans to reduce its stake by up to 8,316,432 shares (2% of total share capital) from December 17, 2024, to March 16, 2025[15]. - BGI Holdings has already reduced its stake by 7,488,300 shares (1.8008% of total share capital) between March 11 and March 14, 2025[15]. - After the reduction, the combined shareholding of BGI Holdings and its concerted parties decreased from 37.34% to 35.53%, without changing the company's control[15]. Research and Development - The company reported a significant increase in research and development expenses, totaling ¥117,331,387.43, up from ¥106,372,298.63 in the previous period, reflecting a growth of 11.5%[24]. - The company has not reported any new product developments or market expansion strategies in the current period[10]. Government Subsidies - The company received government subsidies amounting to ¥2,997,389.85 during the reporting period[3]. Investment Income - The investment income increased by 374.19% to ¥3,416,203.88 from a loss of -¥1,245,924.99 in the previous year[7].

华大基因（300676）公告，2025年第一季度营业收入6.72亿元，同比下降18.18%。净亏损5269.51万 元，去年同期净利润1240.25万元。 ...

截至4月24日收盘，阿尔茨海默概念上涨1.30%，位居概念板块涨幅第6，板块内，21股上涨，金凯生科 20%涨停，双成药业涨停，鲁抗医药、富士莱、东诚药业等涨幅居前，分别上涨3.95%、3.60%、 2.06%。跌幅居前的有诺唯赞、迪安诊断、华大基因等，分别下跌2.96%、2.68%、1.85%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | PEEK材料 | 3.70 | 电子身份证 | -3.20 | | 丙烯酸 | 1.89 | 华为盘古 | -3.13 | | 天津自贸区 | 1.75 | 数字货币 | -3.10 | | 宠物经济 | 1.74 | 数据安全 | -3.07 | | 维生素 | 1.35 | 云办公 | -2.98 | | 阿尔茨海默概念 | 1.30 | 智谱AI | -2.98 | | NMN概念 | 1.22 | 数据确权 | -2.94 | | 人造肉 | 1.06 | 智慧政务 | -2.92 | | CRO概念 | 0.96 | 华为鲲鹏 | -2.92 | | 超超临 ...

（文/观察者网 吕栋 编辑/张广凯） 近日，日本媒体《日经亚洲评论》爆料，美国科技巨头微软不再向中国基因研究公司华大基因提供办公 软件应用程序，包括电子邮件服务。内部邮件称，包括Word、PowerPoint、Excel和Teams在内的许多 Office 365服务都无法再对华大基因员工开放。 观察者网以个人投资者身份就此事联系华大基因方面，对方证券事务工作人员表示，该公司还在跟踪和 落实此事，目前没有什么影响，还在正常运营。 与此同时，今天（4月7日）市场上传出微软停止在华运营和旗下合资公司大裁员的消息。但微软方面下 午公开回应称，"有关微软将停止在中国运营的报道，信息不实。有关微创Wicresoft公司的业务和运营 的任何问题应直接向他们咨询。" 被曝"断供"华大基因办公软件 日媒援引的华大基因内部邮件称，除了Office功能外，微软还将停止向华大基因提供包括Github Copilot 和OpenAI运营的GPT在内的人工智能服务。 目前尚不清楚其他在实体清单上的企业，是否会有类似遭遇。 上个月中旬，观察者网获悉，微软Windows操作系统向华为供货的许可证到期后没有延期，这意味着之 后华为PC只能采 ...

Core Viewpoint - BGI Genomics' stock closed at 51.92 yuan, down 2.55%, with a latest price-to-book ratio of 2.20 and a total market capitalization of 21.589 billion yuan [1] Financial Performance - For the third quarter of 2024, BGI Genomics reported revenue of 2.826 billion yuan, a year-on-year decrease of 10.10% [1] - The net profit for the same period was -124.166 million yuan, representing a year-on-year decline of 276.49% [1] - The gross profit margin stood at 45.22% [1] Market Activity - On April 3, 2024, BGI Genomics experienced a net outflow of main funds amounting to 22.093 million yuan, with a total outflow of 17.1172 million yuan over the past five days [1] Company Overview - BGI Genomics specializes in providing research services and precision medical testing solutions through multi-omics big data technologies, including gene testing, mass spectrometry, and bioinformatics analysis [1] - The company's main products include prenatal nutrition testing, human amino acid testing, and human vitamin testing [1] Awards and Recognition - BGI Genomics has received several awards, including "2022 ESG Best Social Responsibility Enterprise," "2023 Best Strategic Layout Enterprise for Medical Device Export," and "2022 Annual Investor Relations Gold Award Outstanding IR Company," enhancing its brand recognition and influence [1] Industry Comparison - BGI Genomics has a price-to-earnings (P/E) ratio of -212.46 (TTM) and 232.39 (static), with a market capitalization of 21.589 billion yuan [2] - The industry average P/E ratio is 46.48 (TTM) and 50.12 (static), with an average market capitalization of 107.65 billion yuan [2] - The industry median P/E ratio is 31.96 (TTM) and 31.10 (static), with a median market capitalization of 48.33 billion yuan [2]

Group 1 - The third China International Supply Chain Promotion Expo (Chain Expo) will be held from July 16 to 20, 2025, in Beijing, covering an area of 120,000 square meters [3] - This year's Chain Expo will focus more on the "chain" display logic and innovation aggregation, with a new innovation chain area added to the advanced manufacturing chain [3][4] - The Guangdong Provincial Council for the Promotion of International Trade has successfully promoted the Chain Expo, achieving good results in encouraging enterprises to integrate into the global supply chain [3] Group 2 - Jiechuang Intelligent Technology Co., Ltd. plans to participate in the third Chain Expo, showcasing its latest AI infrastructure and products, which have previously attracted over 200 clients and partners [4] - The company reported significant success at last year's Chain Expo, with over 10 million yuan in orders from Africa and initial orders exceeding 100,000 yuan from Indonesia [4] - Shengjian Medical Supplies Co., Ltd. has also benefited from participating in the Chain Expo, enhancing its brand recognition and gaining valuable domestic and international cooperation opportunities [5] Group 3 - The Guangdong Provincial Council for the Promotion of International Trade announced the first batch of key audience lists, including large state-owned enterprises, industry associations, and overseas business associations [5]

证券代码：300676 证券简称：华大基因 公告编号：2025-015 深圳华大基因股份有限公司 关于控股股东及其一致行动人持股比例变动触及 1%整数倍及减 持计划期限届满暨实施结果的公告 控股股东深圳华大基因科技有限公司及其一致行动人汪建先生、深圳华大三 生园科技有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 华大控股本次减持完毕后，控股股东及其一致行动人汪建先生、深圳华大三生 园科技有限公司（以下简称华大三生园）持有公司股份比例从37.34%减少至35.53%， 持股比例变动触及1%整数倍。根据《上市公司收购管理办法》《证券期货法律适用 意见第19号——<上市公司收购管理办法>第十三条、第十四条的适用意见》《上市 公司股东减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第18号 1 ——股东及董事、监事、高级管理人员减持股份》等相关规定，现将本次减持计划 的实施结果及相关权益变动情况公告如下： 一、控股股东本次减持计划的实施情况 （一）控股股东本次减持股份情况 华大控股本次减持的股份来 ...